Pudjihartono N, Ho D, OSullivan J
Front Genet. 2024; 15:1448363.
PMID: 39175752
PMC: 11338781.
DOI: 10.3389/fgene.2024.1448363.
Stasik K, Filip R
Int J Mol Sci. 2024; 25(8).
PMID: 38673824
PMC: 11049907.
DOI: 10.3390/ijms25084241.
Semenzato G, Calabretto G, Teramo A, Gasparini V, Rampazzo E, Barila G
Blood Cancer J. 2024; 14(1):13.
PMID: 38238319
PMC: 10796758.
DOI: 10.1038/s41408-024-00977-0.
Bagnara D, Mazzarello A, Ghiotto F, Colombo M, Cutrona G, Fais F
Int J Mol Sci. 2022; 23(22).
PMID: 36430731
PMC: 9693457.
DOI: 10.3390/ijms232214249.
Semenzato G, Teramo A, Calabretto G, Gasparini V, Zambello R
Leukemia. 2022; 36(11):2551-2557.
PMID: 36109593
DOI: 10.1038/s41375-022-01695-x.
B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.
Bock T, Bewarder M, Cetin O, Fadle N, Regitz E, Schwarz E
EJHaem. 2022; 3(3):739-747.
PMID: 36051037
PMC: 9421956.
DOI: 10.1002/jha2.475.
Diverse mutational landscapes in human lymphocytes.
Machado H, Mitchell E, Obro N, Kubler K, Davies M, Leongamornlert D
Nature. 2022; 608(7924):724-732.
PMID: 35948631
PMC: 9402440.
DOI: 10.1038/s41586-022-05072-7.
Somatic Mutations and Autoimmunity.
Alriyami M, Polychronakos C
Cells. 2021; 10(8).
PMID: 34440825
PMC: 8394445.
DOI: 10.3390/cells10082056.
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.
Flumann R, Rehkamper T, Nieper P, Pfeiffer P, Holzem A, Klein S
Blood Cancer Discov. 2021; 2(1):70-91.
PMID: 33447829
PMC: 7806186.
DOI: 10.1158/2643-3230.BCD-19-0059.
Role of Specific B-Cell Receptor Antigens in Lymphomagenesis.
Thurner L, Hartmann S, Neumann F, Hoth M, Stilgenbauer S, Kuppers R
Front Oncol. 2020; 10:604685.
PMID: 33363034
PMC: 7756126.
DOI: 10.3389/fonc.2020.604685.
Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.
Young R, Phelan J, Wilson W, Staudt L
Immunol Rev. 2019; 291(1):190-213.
PMID: 31402495
PMC: 6693651.
DOI: 10.1111/imr.12792.
The riddle of lymphoma BCR-antigenes.
Thurner L, Hartmann S, Preuss K, Bewarder M
Oncotarget. 2018; 9(88):35805-35806.
PMID: 30533194
PMC: 6254678.
DOI: 10.18632/oncotarget.26318.
Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.
Young R, Wu T, Schmitz R, Dawood M, Xiao W, Phelan J
Proc Natl Acad Sci U S A. 2015; 112(44):13447-54.
PMID: 26483459
PMC: 4640740.
DOI: 10.1073/pnas.1514944112.
Targeting pathological B cell receptor signalling in lymphoid malignancies.
Young R, Staudt L
Nat Rev Drug Discov. 2013; 12(3):229-43.
PMID: 23449308
PMC: 7595252.
DOI: 10.1038/nrd3937.
Self-antigen recognition by follicular lymphoma B-cell receptors.
Sachen K, Strohman M, Singletary J, Alizadeh A, Kattah N, Lossos C
Blood. 2012; 120(20):4182-90.
PMID: 23024238
PMC: 3501716.
DOI: 10.1182/blood-2012-05-427534.
Autoimmunization-A Possible Mechanism of Tissue Injury : III-Clinical Aspects of Autoimmunity.
Steiner J, Volpe R
Can Med Assoc J. 2010; 84(23):1297-302.
PMID: 20326781
PMC: 1847971.
Autoimmunity and lymphomagenesis.
Goldin L, Landgren O
Int J Cancer. 2008; 124(7):1497-502.
PMID: 19089924
PMC: 2666348.
DOI: 10.1002/ijc.24141.
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.
Young R, Hardy I, Clarke R, Lundy N, Pine P, Turner B
Blood. 2008; 113(11):2508-16.
PMID: 18981293
PMC: 2947310.
DOI: 10.1182/blood-2008-05-158618.
B-cell receptor signaling in the genesis and maintenance of B-cell lymphoma.
Young R, Turner B, Refaeli Y
Future Oncol. 2008; 4(5):591-4.
PMID: 18922114
PMC: 2575750.
DOI: 10.2217/14796694.4.5.591.
The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas.
Refaeli Y, Young R, Turner B, Duda J, Field K, Bishop J
PLoS Biol. 2008; 6(6):e152.
PMID: 18578569
PMC: 2435152.
DOI: 10.1371/journal.pbio.0060152.
